Mr VanOort also joined the company’s board of directors. As part of this move, NeoGenomics has modified its by-laws to increase the size of its board of directors to eight members.
Michael Dent, founder of NeoGenomics, will step down as chairman of the board, but remain a member of the board of directors. Robert Gasparini remains president and chief scientific officer.
The company also reported that Mr VanOort has made a $500,000 investment into NeoGenomics by purchasing 625,000 shares of common stock at a purchase price of $0.80 per share.
Mr VanOort has spent over 10 years in healthcare services, first as executive vice president and CFO of Corning Life Sciences and then as senior vice president of operations at Quest Diagnostics.
Dr Dent said: “It gives me great pleasure to welcome Doug VanOort to our team. His track record in our industry is outstanding, and it is a testament to NeoGenomics that a company of our size attracted an executive with his skills, talents, and experience. We believe Doug will be instrumental in helping us reach our goal of achieving $100 million in annual revenue over the next three years.”